Medscape

Intramuscular Aripiprazole May Be Effective Against Acute Agitation in Psychosis

Oct. 13, 2004 (Stockholm) — The atypical antipsychotic aripiprazole (Abilify) is as effective as haloperidol and significantly more effective than placebo at treating acute agitation in psychotic ...
Business Wire

ABILIFY® (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY® (aripiprazole) Injection, an injectable ...
Business Wire

Clinical Study Shows Intramuscular Administration of Aripiprazole (ABILIFY(R)) Significantly Improves Acute Agitation in Patients With Schizophrenia

NEW YORK-- (BUSINESS WIRE)--Patients with schizophrenia, schizoaffective and schizophreniform disorders who received treatment with intramuscular (IM) administration of aripiprazole (ABILIFY (R)) ...
Monthly Prescribing Reference

Phase 3 Study of Aripiprazole Intramuscular Depot for the Maintenance Treatment of Schizophrenia

Otsuka and Lundbeck announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the ...
Monthly Prescribing Reference

Results from First-of-Kind Abilify Maintena Study Announced

ABILIFY MAINTENA (aripiprazole) 300mg and 400mg ext-rel injectable suspension Otsuka and Lundbeck announced results from the first-of-its-kind study comparing the effectiveness of aripiprazole ...
FiercePharma

U.S. FDA Approves Dual-Chamber Syringe for Abilify Maintena® (aripiprazole) Extended-Release Injectable Suspension for the Treatment of Schizophrenia

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) ...
FiercePharma

FDA Approves Deltoid Injection Site for Abilify Maintena® (aripiprazole) for extended-release injectable suspension in the Treatment of Schizophrenia

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc. (OAPI) and Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has expanded the label of ...
The Globe and Mail

FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or ...

Otsuka America Pharmaceutical, Inc. (Otsuka) and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ABILIFY ASIMTUFII ® (aripiprazole) ...
PharmiWeb

Abilify Maintena® 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia

Aripiprazole’s new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months 1. Aripiprazole once-every-two-months LAI is a new formulation containing 960 mg ...
Healthline

Abilify vs. Rexulti: What You Should Know

Abilify (aripiprazole) and Rexulti (brexpiprazole) are prescription drugs used to treat schizophrenia and depression. Both drugs come as tablets that you take once per day. Abilify is also available ...
Yahoo Finance

Health Canada Approves Otsuka and Lundbeck's (Pr)ABILIFY ASIMTUFII® (aripiprazole), the First-and-Only, Once-Every-Two-Months, Long-Acting Injectable (LAI) Treatment for ...

MONTREAL, Jan. 20, 2025 /CNW/ - Otsuka Pharmaceutical Canada Inc. (Otsuka) and Lundbeck Canada Inc. (Lundbeck) announce that Health Canada has issued a Notice of Compliance for ABILIFY ASIMTUFII ® ...